Physician profile
Ashraf A Uddin
NPI 1699262782
$762.93
in general payments reported to CMS, 2019-2025
18 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.40 · 2022: $32.27 · 2023: $172 · 2024: $207 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings Ltd | $133.09 | 2023 | Mycapssa |
| Abbott Laboratories | $96.40 | 2019 | |
| Novo Nordisk INC | $93.69 | 2022-2025 | Sogroya, Wegovy |
| Dexcom, INC. | $66.21 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $62.80 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $37.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $31.10 | 2024 | |
| Sequel Med Tech, LLC | $27.45 | 2025 | Twiist |
| Insulet Corporation | $25.83 | 2025 | Omnipod |
| Rhythm Pharmaceuticals, INC. | $24.35 | 2025 | Imcivree |
| Xeris Pharmaceuticals, INC. | $24.13 | 2024 | Recorlev |
| Beta Bionics, INC. | $23.76 | 2024 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $23.52 | 2024 | Unithroid |
| Embecta Corp. | $21.61 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Lilly USA, LLC | $19.00 | 2024 | Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.63 | 2025 | Minimed 780g |
| Antares Pharma, INC. | $16.84 | 2025 | Xyosted |
| Lexicon Pharmaceuticals, INC. | $16.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.